Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Concomitant Chronic Inflammatory Demyelinating Polyneuropathy and Myasthenia Gravis Following Cytomegalovirus Infection
J Neurol Sci 240:103-106, Mori, M.,et al, 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Morvan's Fibrillary Chorea: A Paraneoplastic Manifestation of Thymoma
JNNP 65:857-862, Lee,E.K.,et al, 1998
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Clinical Uses of Intravenous Immunoglobulins
Ann Int Med 112:278-292, Berkman,S.A.,et al, 1990
Immunologic Aspects of Neurological & Neuromuscular Diseases
JAMA 258:2970-2973, Zweiman,B.&Arnason,B.G.W., 1987
Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
JNNP 35:385, Patten,B.M.,et al, 1972
Neurologic Manifestations of SLE 1972
Nebraska State Journ Med, Oct 1972, pp 395., Aita,J., 1972
Clinicopathologic Conference, Brain Abscess Due to Infection with Listeria Monocytogeneses
NEJM 391:1529-1538, Case 33-2024, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016
Differential Diagnosis of Finger Drop
Neurologist 19:128-131, Varatharaj, A.,et al, 2015
Overlooked non-motor Symptoms in Myasthenia Gravis
JNNP 84:989-994, Suzuki, S.,et al, 2013
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Incidence and Mortality Rates of Myasthenia Gravis and Myasthenic Crisis in US Hospitals
Neurol 72:1548-1554, Alshekhlee,A.,et al, 2009
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
Immunosuppressant Drugs for Myasthenia Gravis
JNNP 80:5-6, Hart,I.K.,et al, 2008
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
IV Immunoglobulin in Patients With Myasthenia Gravis
Neurol 68:837-841,803, Zinman,L., et al, 2007
Evidence Report: The Medical Treatment of Ocular Myasthenia (An Evidence-Based Review)
Neurol 68:2144-2149, Benatar,M. &Kaminski,H.J., 2007
Extrathymic Tumors in Patients With Myasthenia Gravis, A 35-Year Retrospective Study
The Neurologist 12:53-55, Wakata,N.,et al, 2006
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
The Neurologist 12:231-239, Kusner,L.,et al, 2006
Primary CNS Lymphoma in Myasthenic on Long-term Azathioprine
J NeuroOncol 74:91-92, Finelli,P.F., 2005
Primary CNS Lymphoma Complicating Treatment of Myasthenia Gravis with Mycophenolate Mofetil
Neurol 65:639-641, Vernino,S.,et al, 2005
Treatment of Myasthenia Gravis Exacerbation with Intravenous Immunoglobulin
Arch Neurol 62:1689-1693, Gajdos,P.,et al, 2005
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004